Aurinia Pharmaceuticals (AUPH) announced that it has completed an analysis of the first 7 patients to complete 24 weeks in its open-label AURION study. At 24 weeks 57% (n=4/7) of patients continued to be in complete remission as measured by a urinary protein creatinine ratio of ? 0.5mg/mg, eGFR within 20% of baseline and concomitant steroid dose of < 5mg/day. Top-line results will be reported later this year.